F S&P 500
5,008.00 -41.00 (-0.81%) F Dow Jones
37,715.00 -292.00 (-0.77%) F Nasdaq
17,379.25 -168.00 (-0.96%) E-mini Russell 2000 Index Futur
1,937.00 -21.10 (-1.08%) Petróleo
84.42 +1.69 (+2.04%) Oro
2,402.70 +4.70 (+0.20%)
CureVac N.V. (CVAC)
Fuera de horario:
CureVac N.V.
Friedrich-Miescher-Strasse 15
Tübingen 72076
Germany
49 7071 9883 0
https://www.curevac.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 904
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Pierre Kemula B.Sc. | MD, CFO & Member of Management Board | 585.63k | N/D | 1975 |
| Dr. Malte Greune Ph.D. | COO, Member of Management Board & MD | 455.45k | N/D | 1965 |
| Dr. Ulrike Gnad-Vogt M.D., Ph.D. | Senior VP & Area Head of Oncology | 373.94k | N/D | 1973 |
| Dr. Alexander Zehnder M.B.A., M.D. | CEO, MD & Member of Management Board | N/D | N/D | 1970 |
| Dr. Myriam Mendila M.D. | Chief Development Officer, MD & Member of the Management Board | N/D | N/D | 1966 |
| Dr. Sarah Fakih | Vice President Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Mr. Marco Rau L.L.M., Ph.D. | General Counsel | N/D | N/D | N/D |
| Mr. Thorsten Schuller | Head of Corporate Communications | N/D | N/D | N/D |
| Slavica Stevanovic-Heck | Head of Human Resources | N/D | N/D | N/D |
| Dr. Patrick Baumhof | Senior Vice President of Technology | N/D | N/D | N/D |
Descripción
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Gestión corporativa
La calificación ISS Governance QuickScore de CureVac N.V. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
